- Sandip Kapadia, CFO of Harmony Biosciences, sold 20,961 shares in an open-market transaction, fully exiting his direct equity ownership on Jan. 15, 2026, with a transaction value of about $752,800.
- The sale follows a series of prior dispositions by Kapadia, reducing his direct holdings from 72,948 shares to zero. The weighted-average sale price was $35.92 per share, slightly below the market close of $36.41 on Jan. 15, 2026.
- Harmony Biosciences specializes in rare neurological disease therapies, with its successful product WAKIX addressing narcolepsy. The company is expected to achieve over $1 billion in revenue from WAKIX by the end of 2026.
- With strong financial results and promising outlook, Harmony Biosciences looks like a solid investment option in the biomedical sector, especially with its exclusive license for WAKIX and other advanced medications in development.
Read more at NASDAQ: Harmony Biosciences’ CFO Sells All of Her Insider Shares, Worth $752,800